Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409292 · ClinicalTrials.gov registry record · Phase 2
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00409292 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 33 participants.
The verdict
NCT00409292, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate if RAD001 is an effective treatment for pancreatic cancer that has spread and not responded to treatment. Experiments have shown that RAD001 can prevent cells from multiplying. RAD002 has also been tested in laboratory experiments imitating cancer conditions and the results have been promising.
Interventions
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00409292
The ClinicalTrials.gov registry entry for NCT00409292 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001 is the first listed.
NCT00409292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00409292 about?
NCT00409292 is a clinical study titled "RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer". The purpose of this research study is to investigate if RAD001 is an effective treatment for pancreatic cancer that has spread and not responded to treatment. Experiments have shown that RAD001 can prevent cells from multiplying. RAD002 has also been tested in laboratory experiments imitating cancer...
What is the current status of trial NCT00409292?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2007-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00409292?
The interventions under investigation include: RAD001 (DRUG).
Who is sponsoring clinical trial NCT00409292?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.